In the field of biopharmaceuticals, antibody drugs have become the core track of global pharmaceutical innovation due to their precise targeting, excellent efficacy, and low toxicity. From the commercialization competition of PD-1/PD-L1 inhibitors to the rise of ADCs and bispecific antibodies, every technological breakthrough is accompanied by a deep game of patent layout. An antibody drug takes an average of 10-12 years from research and development to market, with a single drug investment of over 2 billion US dollars. More than 60% of its core value comes from a scientific and systematic patent layout.
This article systematically breaks down the full cycle layout strategy of antibody patents, covering research and development, production, definition of protection scope, and helping biopharmaceutical companies avoid patent layout risks.

1、 The value of antibody patent layout
The layout of antibody patents is not a single patent application, but a strategic project that revolves around the entire process of antibody research and development, production, and application. By planning patent combinations, application paths, and protection scopes, a comprehensive technology protection network is constructed. The core is to “carry innovative value with patents and control market discourse power”. For biopharmaceutical companies, valuing patent layout is an inevitable requirement of technological characteristics, market competition, and policy environment.

2、 Why must we attach importance to the layout of antibody patents?
The necessity of antibody patent layout can be clarified from three core dimensions: technological research and development characteristics, market competition pattern, and policy compliance requirements. The three are interrelated and indispensable;

2.1 From the perspective of technological research and development, antibody drug development has significant characteristics such as long cycles, huge capital investment, and extremely low success rates (less than 10%). If there is a lack of comprehensive patent protection throughout the entire development process, even if the technical bottleneck is successfully overcome and qualified products are developed, it is highly likely to be quickly replicated by competitors through reverse engineering, imitation, and other methods, ultimately resulting in the huge R&D costs invested by the enterprise in the early stage being wasted and unable to achieve commercial transformation of R&D results.

2.2 From the perspective of market competition, the antibody drug track has a vast market space. By 2023, the global market size has exceeded 200 billion US dollars. Leading companies in the industry such as Roche and Regenerative Yuan have built solid patent monopoly barriers with over 500 core patents accumulated in their hands, firmly occupying a dominant position in the market. For small and medium-sized pharmaceutical companies, in order to break through the fierce market competition, they must start patent layout work from the early stage of research and development, explore their own technological differentiation advantages through precise technical positioning, and then seize market share in segmented markets, breaking the monopoly pattern of top enterprises.

2.3 From the perspective of policy compliance, China’s Patent Law has explicitly included biological features such as gene sequences and antibody structures as objects of patent protection, but the authorization of such patents must strictly meet the four core conditions of “novelty, creativity, practicality, and full disclosure”. Only by standardizing the layout of patents can enterprises ensure that the innovative achievements of antibody research and development receive legal and effective protection, while effectively avoiding the risk of infringement litigation caused by improper patent layout, and ensuring that the entire process of enterprise research and development, production, and commercialization conforms to industry regulatory trends.

3、 Antibody Patent Layout Strategy
The layout of antibody patents revolves around the two core stages of research and development and production, and develops targeted strategies based on technical nodes.

3.1 Research and Development Stage
The patent layout in the research and development stage needs to closely follow the three core R&D links of “target screening, molecular design, and functional verification”, and combine the essence of technology and innovation points to form a hierarchical and precise patent protection system.

3.1.1 Target screening
In the target screening stage, the core nodes focus on the precise identification of antigen epitopes, the analysis of the binding mechanism between antibodies and targets, and the verification of the correlation between targets and specific disease pathological mechanisms. This is the source innovation of the entire antibody development and the first step in patent layout. The layout at this stage needs to break through the limitations of “only protecting the target itself” and focus on building barriers around “limited use” and “innovative methods”
On the one hand, the layout of target disease related patents clearly limits the application of the target in the treatment, diagnosis, or prognosis of specific diseases, rather than simply protecting the structure of the target protein. This is because the target itself, as a naturally occurring biomolecule, has limited patentability, and the “application association between the target and disease” is an innovative extension of the technical solution; On the other hand, for innovative technologies formed during the target screening process, such as novel antigen epitope screening methods and identification techniques for target binding mechanisms, method patents are laid out to protect the research and development path.

3.1.2 Molecular Design Stage
This is the core link of antibody drug innovation, with core technology nodes covering sequence design of antibody variable regions, key structural optimization of complementarity determining regions (CDRs), humanized or fully humanized antibody modification strategies, as well as three-dimensional antibody structure design based on structural biology. These technology nodes directly determine the core performance of antibodies such as targeting, affinity, and immunogenicity.
At this stage, the patent layout is centered around product patents, constructing a three-dimensional protection network of “core sequence+derived variants”: firstly, for the complete amino acid sequences of the heavy and light chain variable regions of the antibody, as well as the core sequence of the CDR region, a structure limited product patent is submitted, which is the “core barrier” of antibody patents. The claims need to accurately define the sequence features through SEQ ID NO to ensure the uniqueness and certainty of the protection scope; Secondly, for high affinity mutants generated during the molecular design process, optimized sequences after humanized modification, and antibody molecules with novel three-dimensional structures, variant product patents will be laid out through divisional applications or patent extensions within the same family; At the same time, for innovative humanized transformation methods, antibody 3D structure design methods, and synchronous layout method patents, a dual protection of “product+method” is formed.

3.1.3 Functional verification phase
The functional verification stage is a crucial transition from laboratory to clinical antibody development. The core technical nodes include quantitative verification of the affinity and specificity of antibody antigen binding, functional evaluation of in vivo and in vitro biological activity, and detection of the pharmacokinetic and toxicological properties of antibodies. The core value of these technical nodes lies in verifying the clinical application potential of antibodies and forming a large number of patentable technical solutions.
The focus of this stage is on method patents, which complement product patents: on the one hand, for innovative in vitro activity detection methods, such as affinity detection optimization methods based on flow cytometry and evaluation methods for killing activity of new cell models, layout in vitro functional verification method patents; On the other hand, innovative models for in vivo efficacy verification (such as humanized tumor mouse models) and improved techniques for pharmacokinetic testing have been developed, and patents for in vivo functional evaluation methods have been laid out. It is worth noting that the method patents at this stage not only prevent competitors from using the same method for antibody validation, but also provide patent support for subsequent clinical data interpretation and product quality control.

3.2 Production Stage
The cost of antibody production accounts for over 30%, and process optimization is the core of cost reduction and efficiency improvement, as well as a link that is easily cracked by reverse engineering. The patent layout focuses on three major directions: process parameters, purification technology, and quality control to prevent infringement risks.

3.2.1 Process parameter optimization: The process parameters for antibody production directly determine the production capacity, quality, and cost of the product, and are the core competitiveness of the production process. The patent layout should focus on key parameters such as cell culture temperature, pH regulation, feeding strategy, cultivation time optimization, expression vector optimization, cell line screening and modification, etc. Through clear parameter limitations, competitors should be prevented from imitating the core production process.

3.2.2 Purification Technology Innovation: Protein purification is a critical step in antibody production, directly affecting the purity, activity, and safety of antibody products, and is also a core focus of process optimization. The patent layout needs to focus on core purification technologies such as affinity chromatography media, optimization of ion exchange conditions, membrane filtration processes, and impurity removal methods (such as methods for removing host cell proteins, DNA, and endotoxins). Through technological innovation, differentiation barriers can be built while reducing purification costs and improving purification efficiency.

3.2.3 Quality Control System: The quality of antibody drugs is directly related to clinical efficacy and medication safety, and is also a key focus of industry regulation. It is also an important component of patent layout. The key focus is on quality control related technologies such as endotoxin testing methods, aggregate content standards, purity testing processes, stability testing methods, and host cell residue testing methods. This can ensure that products meet domestic and international regulatory requirements, pass clinical trials and market approvals smoothly, and further expand technical barriers and enhance product competitiveness through unique quality control methods.

4、 Definition of the scope of antibody patent protection

According to the Chinese Patent Law, the scope of protection of a patent shall be based on the technical solution recorded in the claims. The specification and drawings are only used to interpret the claims and shall not exceed the scope of protection defined in the claims. In combination with the characteristics of antibody technology and the practice of patent agency, the precise definition of the scope of protection must firmly grasp the following three core requirements:

4.1 Core claims require precise targeting of antibody core technical features
The core claims are the core carriers of antibody patent protection, which need to clearly define the core structural features of the antibody, focusing on the complete amino acid sequences of the antibody’s heavy chain variable region and light chain variable region, as well as the core sequence of the complementarity determining region (CDR region). The writing process should be precise, concise, and clear, avoiding vague expressions, excessive generalization, or insufficient limitation. At the same time, the technical solutions defined by the core claims need to fully correspond to the embodiments in the specification, ensuring that each limiting feature can obtain data support from the embodiments, which can effectively lock in the core antibody technology, prevent core infringement by competitors, and provide a solid technical basis for patent authorization.

4.2 Dependent claims need to enrich protection dimensions and enhance patent stability
Dependent claims are supplementary and further limiting to core claims, and their core function is to expand the dimensions of patent protection and enhance patent stability. In antibody patents, dependent claims can supplement and limit the functional features, usage features, preparation method features, etc. of the antibody based on the core claims. Functional features may include the binding affinity between the antibody and the corresponding antigen, as well as the biological activity of the antibody; The use characteristics can include the application of antibodies in the treatment and diagnosis of specific diseases (such as limited to the treatment of HER2 positive breast cancer, non-small cell lung cancer, etc.); The characteristics of the preparation method may include specific technical pathways such as antibody screening, expression, and purification. By supplementing the limitations of dependent claims, the boundaries of patent protection can be further refined and the stability of the patent can be enhanced. Even if the core claims are partially invalidated due to the questioning of certain limiting features, dependent claims may still remain valid due to more specific and sufficient support, continuing to play a role in patent protection.

4.3 Reasonable use of general descriptions to prevent technology and mitigate risks
In the process of drafting the claims, open-ended expressions such as “including”, “selected from”, and “having at least 90% (or 95%, 98%) sequence identity” can be reasonably used to provide general protection for homologous sequences, mutants, derivatives, etc. of antibodies, covering various antibody variants with similar structures and functions, further expanding the scope of patent protection, and preventing competitors from evading patent protection through sequence homology substitution, site mutations, and other means. However, it should be noted that the application of general descriptions must grasp reasonable boundaries and be fully supported by the embodiments in the specification, ensuring that technical personnel in this field can reasonably derive all technical solutions within the scope of the summary based on the embodiments in the specification, and avoid patent failure or invalidity due to excessive generalization or lack of support.

5、 New trends in patent development in antibody research and development
With the rapid iteration of antibody research and development technology and the continuous upgrading of clinical demand, the global number of antibody patent applications continues to rise, and the hotspots of patent layout are also constantly changing. According to statistics from Nature Biotechnology in 2023, the average annual growth rate of global antibody patent applications is 15%, with China accounting for over 30% of antibody patent applications, making it one of the core markets for global antibody innovation and patent layout.
Based on the latest developments in antibody research and industry trends, the following three types of technologies have become the core hotspots of patent layout and the key directions of future antibody patent layout, which are worthy of the attention and layout of enterprises.

5.1 Bispecific antibodies

Bispecific antibodies – with the fastest growth rate in patent layout and the most intense competition. Bispecific antibodies have become a core hotspot in antibody research and development due to their ability to simultaneously bind to two different targets, synergistically exert therapeutic effects, reduce off target effects, and improve clinical efficacy. They are also the field with the fastest growth rate in patent layout.
The patent layout of bispecific antibodies mainly focuses on three core technology nodes: firstly, the design of the dual target binding region, including the amino acid sequence, structural form (IgG like, non IgG like), and optimization of the binding site of the dual target binding domain. This is the core technology of bispecific antibodies and also the focus of patent protection; The second is the regulation of effector functions, including the optimization and regulation of antibody ADCC effect, CDC effect, antibody dependent cell phagocytosis (ADCP) and other effector functions, aiming to improve clinical efficacy and reduce toxic side effects; The third is half-life extension technology, which extends the half-life of bispecific antibodies in vivo through Fc segment modification, PEG modification, fusion protein and other methods, improving medication convenience and clinical efficacy.

5.2 ADC drugs
As a fusion product of “antibody+chemotherapy drug”, antibody conjugated drugs (ADCs) combine the precise targeting of antibodies with the strong cytotoxicity of chemotherapy drugs, demonstrating excellent therapeutic effects in the field of tumor treatment. They have become another hot topic in global antibody drug research and development, and are also one of the core focuses of patent distribution. The core patent layout of ADC drugs mainly focuses on three directions: firstly, antibody drug coupling sites, including natural amino acid coupling sites, non natural amino acid insertion sites, etc. The selection of coupling sites directly affects the stability, efficacy, and toxic side effects of ADC drugs, and is the focus of patent protection; The second is the stability of linkers, including the design and optimization of cleavable and non cleavable linkers. cleavable linkers can specifically cleave in the tumor microenvironment, release chemotherapy drugs, improve efficacy, and reduce toxic side effects, which is currently a hot topic in patent layout; The third is drug loading screening, including the screening and coupling of novel cytotoxic drugs, aimed at enhancing the anti-tumor activity of ADC drugs and reducing toxic side effects.

5.3 Multispecific Nanobodies
Multispecific nanobodies possess advantages such as small molecular weight, strong penetration, ease of modification, and low immunogenicity. They can bind to “recessed epitopes” and “concealed epitopes” that are difficult for traditional antibodies to bind to, and have broad application prospects in areas such as tumor treatment, autoimmune disease treatment, and anti-infection therapy. They are also an emerging hotspot in current antibody research and development. The patent layout of multispecific nanobodies primarily focuses on three core technological nodes: first, VHH domain optimization, including amino acid sequence optimization, affinity enhancement, and stability optimization of the VHH domain; second, multivalent tandem design, by linking multiple VHH domains in tandem to construct multispecific nanobodies, achieving simultaneous binding to multiple targets and enhancing clinical efficacy; third, targeted delivery enhancement, by modifying nanobodies to improve their targeting and penetration ability towards target cells and reduce off-target effects. Additionally, the preparation process, half-life extension technology, and clinical applications of multispecific nanobodies have also become important directions for patent layout. Currently, the patent landscape in this field is still in a rapid development stage, with significant potential for layout and commercialization.

6. Conclusion
The innovation and iteration of antibody drugs are accelerating globally, and patent layout has become a core component of enterprises’ core competitiveness. From targeting R&D to optimizing production processes, from defining protection scope to deploying cutting-edge technologies, the quality of patent layout in every link determines the enterprise’s voice in the industry. In the future, only by closely following technological trends such as bispecific antibodies and ADCs, and building a systematic and multi-level patent protection system, can enterprises break through in the global antibody competition and promote industry innovation and upgrading.

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com